INO Inovio Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: INO

Price (delayed)

$1.43

Market cap

$267.85M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.54

Enterprise value

$228.17M

?
Relative Growth: Rel. Growth: 36
Relative Strength: Rel. Strength: 78
Relative Valuation: Rel. Valuation: 1
Relative Profitability: Rel. Profitability: 29

The complaint alleges that Inovio and certain officers made materially false and misleading statements regarding medical device manufacturing and FDA regulatory pathway eligibility during the Class Period of October 10, ...

Highlights
INO's EPS has surged by 79% year-on-year and by 41% since the previous quarter
INO's revenue has soared by 64% year-on-year
INO's net income is up by 34% year-on-year but it is down by 5% since the previous quarter
INO's quick ratio is down by 41% since the previous quarter and by 27% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.inovio.com
Peers: PFE JNJ ARWR NVS

Key stats

What are the main financial stats of INO

INO stock price

How has the Inovio Pharmaceuticals stock price performed over time
Intraday
-2.05%
1 week
17.7%
1 month
43.26%
1 year
-26.67%
YTD
-17.82%
QTD
17.21%

Financial performance

How have Inovio Pharmaceuticals's revenue and profit performed over time
Revenue
$298,901
Gross profit
$298,901
Operating income
-$77.58M
Net income
-$71.14M
Gross margin
100%
Net margin
-23,798.9%
INO's revenue has soared by 64% year-on-year
The gross profit has surged by 64% year-on-year
Inovio Pharmaceuticals's net margin has surged by 60% YoY
The company's operating margin rose by 47% YoY

Price vs fundamentals

How does INO's price correlate with its fundamentals

Growth

What is Inovio Pharmaceuticals's growth rate over time

Valuation

What is Inovio Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
471.88
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
763.36
INO's EPS has surged by 79% year-on-year and by 41% since the previous quarter
INO's revenue has soared by 64% year-on-year
The P/S is 31% higher than the 5-year quarterly average of 360.6

Efficiency

How efficient is Inovio Pharmaceuticals business performance
INO's return on sales has surged by 60% year-on-year
INO's return on assets is down by 10% since the previous quarter but it is up by 4.8% year-on-year

Dividends

What is INO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for INO.

Financial health

How did Inovio Pharmaceuticals financials performed over time
The total assets is 36% smaller than the total liabilities
The company's total liabilities has surged by 109% QoQ and by 22% YoY
INO's current ratio is down by 43% QoQ and by 28% YoY
Inovio Pharmaceuticals's debt is 121% higher than its equity
The debt to equity has plunged by 111% from the previous quarter but it has soared by 84% YoY
Inovio Pharmaceuticals's debt has decreased by 27% YoY and by 9% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.